Supernus Pharmaceuticals Inc
SUPN
查看详细走势图
49.520USD
-1.275-2.51%
收盘 03/27, 16:00（美东）报价延迟15分钟
1.18B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-2.51%
5天
+3.69%
1月
-9.52%
6月
+5.29%
今年开始到现在
-0.36%
1年
+52.75%
查看详细走势图
TradingKey Supernus Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Supernus Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名41/157位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价63.17。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Supernus Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
极度看空
Supernus Pharmaceuticals Inc亮点
亮点风险
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
业绩高增长
公司营业收入稳步增长，连续3年增长18.34%
业绩转亏
公司业绩转亏，最新年度亏损美元
估值低估
公司最新PE估值-72.52，处于3年历史低位
机构减仓
最新机构持股59.41M股，环比减少6.94%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值673.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.95
分析师目标
根据
6
位分析师
买入
评级
63.167
目标均价
+27.92%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Supernus Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Supernus Pharmaceuticals Inc简介
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
公司代码SUPN
公司Supernus Pharmaceuticals Inc
CEOKhattar (Jack A)
网址https://www.supernus.com
相关品种
